PILOT AND FEASIBILITY STUDIES (PFS) FOR 2017-2018

Letter of Intent Due - September 25, 2017

The CURE: Digestive Diseases Research Center (CURE: DDRC) and the UCLA Clinical and Translational Science Institute (CTSI) invite applications (new or second year renewal) for the 2017-2018 academic year. Funding will be available for high quality and innovative research in the biology, function and diseases of the digestive system, which is of relevance to the overall CURE Research Program, with special emphasis on receptor and signal transduction mechanisms, brain-gut interactions, gastrointestinal and pancreatic physiology and inflammation, and mechanisms underlying diseases of the digestive system. Proposed projects should lead to peer-reviewed extramural funding such as NIH, VA or related agency research grants in which PFS awardees serve as Principal Investigators. Awards range from $25,000 to $35,000/year.

ELIGIBILITY:

Category 1. New investigators without current or past independent NIH or related agency research support as principal investigators, who are seeking to establish their own independent research program. Young investigators supported by Career Development or Mentor awards (e.g. K01, K08 or similar) are considered eligible for category 1 and encouraged to apply for PFS funding

Category 2. Established investigators with currently active research support, who have not been involved in research of the digestive system and who want to enter this field of research.

Category 3. Established investigators with currently active support for research in the digestive system, who want to pursue a new research direction in the field of gastroenterology, which represents a significant departure from their funded research.

Highly innovative proposals are encouraged. Category 1 is given preference.

AWARD TERMS:

1.     Applicants must hold a Ph.D., M.D. or equivalent degree and have at least 3 years of postgraduate research experience.

2.     Trainees who are recipient of an NRSA individual award (F32) or are supported by an institutional training grant (T32), or fellowship are eligible in their last year of training.

3.     Applicants must have a UCLA appointment in an academic track (research fellows or postdoctoral scholars are included) by the time of the award.

4.     New investigators without independent support need to provide documentation of support (i.e. space available and financial support beyond the PFS fund) of a UCLA or VA faculty sponsor.

5.     An investigator is eligible only once for PFS support with the exception of new investigators (category 1) whose previous PFS has resulted in independent funding and are now eligible to apply as category 3.

6.     Applicants are required to use at least one Center core in addition to the Administrative Core (see website for list of Cores and services at http://www.cure.med.ucla.edu) and must perform research at CURE (VA or UCLA) and/or UCLA only.

7.     Applications establishing collaborative interactions within the Center are encouraged.

8.     CTSI Reporting Requirements will be distributed at the time of the award notification.

APPLICATION PROCESS:

LETTER of INTENT: A one-page letter of intent and the applicant’s NIH-style biosketch should be submitted by September 25, 2017 as e-mail attachment to the program coordinator, Jacqueline Ismen (JIsmen@mednet.ucla.edu). The letter of intent should include 1) the applicant name, rank and affiliation, 2) the category (see eligibility for the categories) for which the applicant wishes to apply, 3) the proposal title, 4) the hypothesis and a paragraph describing the salient features of the project, 5) which core(s) of the CURE: DDRC will be used, 6) the mentor’s funded research project(s), if the applicant is a junior investigator without independent funding, or of other funded project(s), if the applicant is a senior investigator, and 7) how the proposed project will differ from the funded projects. If the applicant is a PFS awardee who wishes to apply for a second year funding, a progress report of past supported research must be added to the letter of intent for evaluation. Applicants will be notified of their eligibility to submit a full application. The letter of intent (no more than one page in length), the NIH biosketch and the progress report (if applicable) should be submitted as a single pdf document. Documents not conforming will be returned. Applicants will be notified of their eligibility to submit a full application. The template for the letter of intent and instructions for full applications can be found on the CURE:DDRCC website http://www.cure.med.ucla.edu).

FULL APPLICATION DEADLINE:  Full Application Deadline: November 20, 2017; Starting Date: March 1, 2018